- US-listed companies
- AGIOS PHARMACEUTICALS, INC.
- Income statement
AGIOS PHARMACEUTICALS, INC.【AGIO】Income statement
Market cap
$1.6B
P/E ratio
| 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 26 | 65 | - | - | 43 | 94 | 118 | 203 | - | 14 | 27 | 36 |
| Revenue growth (%) | - | - | - | - | - | - | ||||||
| Cost of revenue | - | - | - | - | - | 1 | 1 | 3 | - | 2 | 3 | 4 |
| Research & development | 55 | 100 | 142 | 220 | 293 | 341 | 411 | 367 | 257 | 280 | 296 | 301 |
| Selling, general & administrative | - | - | - | - | - | 114 | 132 | 149 | 121 | 122 | 120 | 157 |
| Operating margin (%) | - | - | - | |||||||||
| Operating income | -39 | -54 | -119 | -201 | -321 | -362 | -426 | -316 | -378 | -389 | -391 | -426 |
| Operating expenses | 64 | 119 | 178 | 271 | 364 | 457 | 544 | 519 | 378 | 403 | 418 | 462 |
| Income before tax | -39 | -54 | -118 | -198 | - | - | - | - | -357 | -232 | -352 | 718 |
| Pretax margin (%) | -152 | -82.5 | - | - | - | - | - | - | - | -1,627.8 | -1,312.6 | 1,967.1 |
| Provision for income taxes | 1 | -0 | - | - | - | - | - | - | - | - | - | 44 |
| Effective tax rate (%) | - | - | - | - | - | - | - | - | - | |||
| Net income | -39 | -54 | -118 | -198 | -315 | -346 | -411 | -327 | 1,605 | -232 | -352 | 674 |
| Net income margin (%) | - | - | - | |||||||||
| Earnings per share | - | - | - | - | - | - | - | - | 26.55 | -4.23 | -6.33 | 11.86 |
| Diluted EPS | - | - | - | - | - | - | - | - | 26.55 | -4.23 | -6.33 | 11.64 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | |
| EBITDA margin (%) | - | - | - | - | - | - | - | - | - | - | - |